Table 4.

Repeated measures analyses of binary secondary outcomes at 2 weeks, 6 weeks, and 12 weeks

		Sertraline		Placebo		Adjusted*OR (95% CI)	p value
		n	n (%)	n	n (%)
Patient Health Questionnaire, 9-item version remission
Follow-up assessment (weeks)
	2	277	145 (52%)	292	136 (47%)	1·36 (0·76–2·41)	..
	6	266	169 (63%)	284	164 (58%)	1·30 (0·72–2·34)	..
	12	262	190 (73%)	263	170 (65%)	1·75 (0·94–3·27)	..
Over time†		..	..	..	..	1·44 (0·93–2·22)	0·10
Group by time interaction		..	..	..	..	..	0·49
Beck Depression Inventory, second edition remission
Follow-up assessment (weeks)
	2	273	58 (21%)	286	58 (20%)	1·01 (0·52–1·98)	..
	6	266	94 (35%)	285	91 (32%)	1·28 (0·70–2·35)	..
	12	256	131 (51%)	259	102 (39%)	2·69 (1·46–4·97)	..
Over time†		..	..	..	..	1·58 (1·00–2·47)	0·049
Group by time interaction		..	..	..	..	..	0·012
Feeling better (self-rated improvement)
Follow-up assessment (weeks)
	2	279	110 (39%)	292	89 (30%)	1·64 (1·06–2·53)	..
	6	267	157 (59%)	285	132 (46%)	1·90 (1·24–2·91)	..
	12	264	156 (59%)	265	112 (42%)	2·42 (1·56–3·75)	..
Over time†		..	..	..	..	1·96 (1·45–2·63)	<0·0001
Group by time interaction		..	..	..	..	..	0·16

CIS-R=Clinical Interview Schedule—Revised.

^*All multilevel models were adjusted for baseline measure of each outcome (continuous), baseline CIS-R depression severity score, and stratification variables (baseline total CIS-R score in three categories, duration of depressive episode in two categories, and site).

^†Calculated using data from all three follow-ups combined.